The National Pharmaceuticals Strategy: Rest in peace, revive or renew?

MacKinnon, Neil J.; Ip, Ivan
April 2009
CMAJ: Canadian Medical Association Journal;4/14/2009, Vol. 180 Issue 8, p801
Academic Journal
In this article the authors discuss the objective of the National Pharmaceuticals Strategy. They point out the strategy's great impact to public policy, especially to the affordability and safety of medication. Two reports from the Health Council Canada regarding the status of health care system in the country and the provision of drug policy initiatives are also discussed.


Related Articles

  • Medication advertising in Brazil. Can it be regulated? Nascimento, Álvaro César // Revista Ciência & Saúde Coletiva;2009, Vol. 14 Issue 3, p869 

    The regulation of medication advertising in Brazil has four weak points. Inspection and punishment of irregularities is carried out a posteriori to the infraction being committed (when the population has already been exposed to a sanitary risk). The fines charged by the Brazilian Sanitary...

  • WASHINGTON report. Dickinson, James G. // Medical Marketing & Media;Oct2000, Vol. 35 Issue 10, p34 

    Presents news briefs related to medical care in the United States, as of October 2000. Pharmaceutical Research & Manufacturers of America's response to the United States Food & Drug Administration's (FDA) proposed over-the-counter drug approval process; Proposed rulemaking on child-resistant...

  • China to Establish Regulatory Biosimilars Framework. Ellis, Shannon // BioWorld International;8/28/2013, Vol. 18 Issue 35, p2 

    The article focuses on the efforts of the Chinese government to develop a regulatory framework and a market for biosimilar products in the country in 2013, in relation to the plan of lowering costs and facilitating better health care outcomes. It explains the coverage of a key platform...

  • Ontario court affirms that medical marijuana regulations are unconstitutional. Cruess, Gordon // Canadian HIV/AIDS Policy & Law Review;Dec2003, Vol. 8 Issue 3, p53 

    Examines the affirmation of the Ontario Court of Appeal which found that the Marijuana Medical Access Regulations (MMAR) represented an unconstitutional barrier to accessing a legal supply of marijuana for persons with a recognized medical need. How the court of Appeal tailored its order;...

  • APPRISE Oncology Program for Erythropoiesis- Stimulating Agents. Hagerty, Karen // Journal of Oncology Practice;May2010, Vol. 6 Issue 3, p157 

    The article focuses on the erythropoiesis-stimulating agent (ESA) Assisting Providers and cancer Patients with Risk Information for the Safe use of ESAs (APPRISE) Oncology Program which is part of the Risk Evaluation and Mitigation Strategy approved by the U.S. Food and Drug Administration (FDA)...

  • Latest Trends in French Policy on Drugs. Simmat Durand, Laurence // European Journal on Criminal Policy & Research;1998, Vol. 6 Issue 3, p415 

    Present French policy with respect to drugs was defined in a government programme ratified at a meeting of the Inter-Ministerial Committee for the Control of Drugs and Drug Abuse, held on September 14, 1995 and headed by the Prime Minister. The present government plan rests on three main lines...

  • FDA Warns Antipsychotic Drugs May Be Risky for Elderly. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;5/25/2005, Vol. 293 Issue 20, p2462 

    Reports the U.S. Food and Drug Administration warned that antipsychotic drugs can increase the death rate in elderly dementia patients. Information from studies on olazapine, aripiprazole, risperidone, and quetiapine; Indication two other atypical antipsychotics approved by the FDA, clozapine...

  • How to get more out of the 340B drug discount program. Belden, Heidi // Drug Topics;1/28/2008, Vol. 152 Issue 2, specia section p10 

    The article reports on the 340B drug discount program from the enactment of the Veterans Health Care Act of 1992. According to the author, many individuals are unaware of the scopes of the program. It also mentions that Harvey Hagel, R.Ph., M.S., senior director of the Health Resources and...

  • South Africa's New National Drug Policy. Zuma, Nkosazana Dlamini // Journal of Public Health Policy;1997, Vol. 18 Issue 1, p98 

    This article focuses on South Africa's new national drug policy. One of the major expenditures in South Africa's health services was drugs. But because there was no drug policy, and hence no coordinated rational drug strategies, the cost of health care was constantly being pushed up. Therefore,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics